Giordano Madeddu to Antiretroviral Therapy, Highly Active
This is a "connection" page, showing publications Giordano Madeddu has written about Antiretroviral Therapy, Highly Active.
Connection Strength
1.234
-
Body fat changes in HIV patients on highly active antiretroviral therapy (HAART): a longitudinal DEXA study. Eur Rev Med Pharmacol Sci. 2018 03; 22(6):1852-1859.
Score: 0.472
-
The burden of HIV-associated neurocognitive disorder (HAND) in post-HAART era: a multidisciplinary review of the literature. Eur Rev Med Pharmacol Sci. 2017 05; 21(9):2290-2301.
Score: 0.446
-
Editorial - HIV and cancer during COVID-19 pandemic: sailing through the perfect storm. Eur Rev Med Pharmacol Sci. 2020 12; 24(24):13103-13104.
Score: 0.143
-
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). J Antimicrob Chemother. 2017 04 01; 72(4):1163-1171.
Score: 0.111
-
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL. J Antimicrob Chemother. 2019 09 01; 74(9):2732-2741.
Score: 0.033
-
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. J Antimicrob Chemother. 2018 07 01; 73(7):1955-1964.
Score: 0.030